Biovac disputes Cipla’s claim it saved government R2.4bn
State-backed vaccine manufacturer says calculation based on inflated demand forecasts and outdated prices
25 April 2023 - 20:09
SA state-backed vaccine manufacturer Biovac has taken issue with Cipla SA’s claim that its pneumonia vaccine will save the health department R2.4bn over the next three years, saying its calculation is based on inflated demand forecasts and outdated prices.
The direct savings are likely to be R280m a year, or R840m over the period, said Biovac...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.